NCT04947592

Brief Summary

Fungal Chorioretinitis is a vision threatening condition.The investigators evaluate the efficacy of SD-OCT role in the treatment

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
10

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2020

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 15, 2020

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

June 24, 2021

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 1, 2021

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2022

Completed
Last Updated

December 15, 2021

Status Verified

December 1, 2021

Enrollment Period

2 years

First QC Date

June 24, 2021

Last Update Submit

December 14, 2021

Conditions

Fungal Retinitis

Keywords

fungalchorioretinitisOCT

Outcome Measures

Primary Outcomes (1)

  • Best corrected visual acuity (BCVA)

    Change in BCVA in LOG MARS(logarithm minimum angle of resolution

    6 months

Secondary Outcomes (1)

  • optical coherence tomography (OCT) foveal thickness

    6 months

Interventions

Fluconazole 150 mgDRUG

fluconazole 150 MG once daily for 14 days

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

at least 18 years old patient with fungal chorioretinitis

You may qualify if:

  • \- fungal chorioretinitis

You may not qualify if:

  • vitritis
  • other macular lesion
  • macular scar

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

INMC

Abu Dhabi, 46266, United Arab Emirates

RECRUITING

MeSH Terms

Conditions

Chorioretinitis

Interventions

Fluconazole

Condition Hierarchy (Ancestors)

RetinitisRetinal DiseasesEye DiseasesChoroiditisChoroid DiseasesUveal DiseasesUveitis, PosteriorPanuveitisUveitis

Intervention Hierarchy (Ancestors)

TriazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • TAREK ELHAMAKY

    Benha University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

TAREK R ELHAMAKY, MD

CONTACT

0503207889thamaky@ibnnafees.com

TAREK ELHAMAKY

CONTACT

0503207889thamaky@ibnnafees.com

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

June 24, 2021

First Posted

July 1, 2021

Study Start

January 15, 2020

Primary Completion

January 1, 2022

Study Completion

January 1, 2022

Last Updated

December 15, 2021

Record last verified: 2021-12

Locations

AE(1)